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PROSTAGLANDINS (PGS)  have  numerous  cardiovascular
and  inflammatory  effects.  Cyclooxygenase  (COX),
which exists as COX-1 and COX-2 isoforms, is the first
enzyme in the pathway in which arachidonic acid is
converted to PGs.  Prostaglandin  E2 (PGE2)  exerts a
variety of biological activities for the maintenance of
local  homeostasis  in  the  body.  Elucidation  of  PGE2
involvement in the signalling molecules such as COX
could  lead  to  potential  therapeutic  interventions.
Here, we have investigated the effects of PGE2 on the
induction of COX-2 in human umbilical vein endothe-
lial cells (HUVEC) treated with interleukin-1b (IL-1b
1 ng/ml). COX activity was measured by the produc-
tion of 6-keto-PGF1a , PGE2, PGF2 a and thromboxane
B2 (TXB2) in the presence of exogenous arachidonic
acids (10 m M for 10min) using enzyme immunoassay
(EIA).  COX-1  and  COX-2  protein  was  measured  by
immunoblotting  using  specific  antibody.  Untreated
HUVEC  contained  only  COX-1  protein  while  IL-1b
treated HUVEC contained COX-1 and COX-2 protein.
PGE2 (3 m M for 24h) did not affect  on COX activity
and protein in untreated HUVEC. Interestingly, PGE2
(3 m M  for  24h)  can  inhibit  COX-2  protein,  but  not
COX-1 protein, expressed in HUVEC treated with IL-
1b . This inhibition was reversed by coincubation with
forskolin  (100 m M).  The  increased  COX  activity  in
HUVEC treated with IL-1b was also inhibited by PGE2
(0.03,  0.3  and  3 m M  for  24 h)  in  a  dose-dependent
manner. Similarly, forskolin (10, 50 or 100 m M) can
also reverse the inhibition of PGE2 on increased COX
activity in IL-1b treated HUVEC. The results suggested
that (i) PGE2 can initiate negative feedback regulation
in the induction of COX-2 elicited by IL-1b in endothe-
lial cells, (ii) the inhibition of PGE2 on COX-2 protein
and  activity in IL-1b treated HUVEC is  mediated by
cAMP  and  (iii)  the  therapeutic  use  of  PGE2 in  the
condition which COX-2 has been involved may have
different roles.
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Introduction
Prostaglandins  (PGs)  have  numerous  cardiovascular
and inflammatory effects.1 Cyclooxygenase (COX) is
the first enzyme in the pathway in which arachidonic
acid is converted to PGs.2,3 COX exists in at least two
isoforms.  One  is  the  constitutive  enzyme,  COX-1,
producing regulatory prostanoids under physiological
conditions,4 whereas the other, COX-2, is induced by
mitogens,5,6 and proinflammatory cytokines7,8 during
pathological states such as inflammation.
The main PGs produced in the body are prostacy-
clin  (PGI2),  PGE2,  PGF2 a , Thromboxane A2 (TXA2)
and  PGD2.  Each  PGs  has  different  characters  and
functions. Among  the  PGs,  PGE2 is  a  potent  lipid
molecule with complex proinflammatory and immu-
noregulatory properties.9 PGE2 is considered a major
contributor  to  the  production  and  maintenance  of
immunosuppression  after  overwhelming  injury.10
PGE2 is believed to modulate biochemical and immu-
nological  events  leading  to parturition.11 PGE2 also
exerts a variety of biological activities for the main-
tenance  of  local  homeostasis  in  the  body.12 Inter-
estingly, we have shown in previous studies that the
induction of COX-2 elicited by endotoxin (lipopoly-
saccharide,  LPS) in  endothelial  cells  is  inhibited  by
PGE1 and  13,14-dihydro  PGE1.13 Elucidation  of  the
effects  of  PGE2 on  the  signalling  molecule  such  as
COX could lead to potential therapeutic interventions
and understanding of the feedback regulation of COX
in  endothelial cells. Here, we have investigated the
effects of PGE2 on the induction of COX-2 in human
umbilical vein endothelial cells (HUVEC) treated with
interleukin-1b (IL-1b ) (1ng/ml).
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Cell culture
Human  umbilical  vein  endothelial  cells  (HUVEC)
were obtained from babies born to normal pregnant
women  as  previously  described14 and  cultured  in
96-well  plates  with  Human  Endothelial-SFM  Basal
Growth  Medium  (Gibco)  containing  10%  fetal  calf
serum (Gibco), 100 units/ml penicillin G sodium and
100 m g/ml  streptomycin.  Cells  were  incubated  at
37°C  in  a  humidified  incubator  and  grown  to  con-
fluence before use.
Measurement of COX activity
Confluent HUVEC were gently washed two times with
phosphate-buffered  saline  (PBS)  and  replaced  with
fresh  medium  (200 m l/well)  before  use.  Cells  were
treated with no addition, IL-1b (1ng/ml), IL-1b (1ng/
ml) plus PGE2 (0.03, 0.3 or 3 m M) or PGE2 (3 m M) alone
for 24 h, after which time the medium was removed
and  washed  twice  with  PBS.  COX  activity  was
measured by the production of four COX metabolites,
e.g. 6-keto-PGF1 a (a stable metabolite of PGI2), PGE2,
Prostaglandin  F2 a (PGF2 a )  and  thromoboxane  B2
(TXB2; a stable metabolite of TXA2) in the replaced
fresh medium containing exogenous arachidonic acid
(10 m M for 10min) using enzyme immunoassay (EIA).
Briefly, 50 m l of standard PGs or samples were added to
pre-coated  mouse  anti-rabbit  IgG  microtitre  plates
(96-well). Then, PGs acetylcholinesterase tracer (Clay-
man; 50 m l) and rabbit antiserum of PGs were added.
The plate was covered with plastic film and incubated
for  18h  at  4°C,  after  which  time  the  wells  were
emptied and rinsed five times with wash buffer (PBS
containing 0.05% Tween). Ellman’s reagent (Cayman;
200 m l) was added to each well and the plates were
shaken on a microtitre plate shaker. The duration of the
reaction was about 90 min. A yellow colour develops
which can be read using a microplate reader (BIORAD;
OD 415 nm).
Immunoblot (Western blot) analysis
HUVEC  which  were  untreated,  treated  with  IL-1b
(1ng/ml), IL-1b (1 ng/ml) plus  PGE2 (0.03,  0.3  and
3 m M) or PGE2 (3 m M) alone were cultured in six-well
culture plates (37°C; for 24h). After 24 h incubation,
cells were extracted and analysed by immunoblotting
using  specific  antibodies  for  COX-1  and  COX-2
protein (a generous gift from Dr Gary O’Neill, Merck
Frosst, Canada) as previously described.15
The other experiment was performed to study the
signalling  molecule  in  the  effects  of  PGE2 on  COX
expression  by  using  forskolin  (cAMP  activator).
HUVEC  were treated with no addition, IL-1b (1ng/
ml), IL-1b (1ng/ml) plus PGE2 (3 m M), IL-1b (1ng/ml)
plus PGE2 (3 m M) with forskolin (10, 50 and 100 m M),
IL-1b (1ng/ml) plus forskolin (100 m M), PGE2 (3 m M)
plus forskolin (100 m M), forskolin (100 m M) alone or
PGE2 (3 m M)  alone  for  24 h,  after  which  time,  the
medium  was  removed  and  replaced  with  fresh
medium  containing  exogenous  arachidonic  acid
(10 m M for 10min). The medium was then removed to
measure  COX  activity  by  6-keto-PGF1 a production.
The remained cells were extracted and analysed by
immunoblotting using specific antibodies for COX-1
and COX-2 protein.
Measurement of cell viability
Cell  respiration,  an  indicator  of  cell  viability,  was
assessed  by  the  mitochondrial-dependent  reduction
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide  (MTT)  to  formazan.16 At  the  end  of  each
experiment,  cells  in  96-well  plates  were  incubated
(37°C; 1h) with MTT (0.2 mg/ml) dissolved in culture
medium, after which time, the medium was removed
by  aspiration  and  cells  were  solubilized  in  DMSO
(200 m l each well). The extent of reduction of MTT to
formazan within cells was quantitated by the meas-
urement of optical density at 650 nm (OD650) using a
microplate reader (BIORAD, USA).
Statistical analysis
The results are shown as mean standard error of the
mean (SEM) of triplicate determinations (wells) from
at  least  four  separate  experimental  days  (n=12).
Student’s  paired  or  unpaired  t-tests,  as  appropriate,
were  used  for  the  determination  of  significance  of
differences between means and a P value of less than
0.05 was taken as statistically significant.
Materials
DMSO,  phosphate  buffered  saline  (PBS;  pH  7.4),
Trizma  base,  EDTA,  triton  X-100,  phenylmethylsul-
phonyl fluoride (PMSF), pepstatin A, leupeptin, glyc-
erol,  bromphenol  blue,  2-mercaptoethanol,  sodium
dodecyl  sulphate  (SDS),  forskolin,  anti-rabbit  IgG
antibody,  goat  IgG,  premixed  BCIP/NBT  solution,
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), penicillin G sodium and streptomy-
cin were supplied by Sigma Chemical Company (St
Louis, MO, USA). PGs (6-keto-PGF1 a , PGE2, PGF2 a and
TXB2) and their respective acetylcholinesterase tracer
and  rabbit  antiserum,  pre-coated  mouse  anti-rabbit
IgG  microtitre plates (96-well) and Ellman’s reagent
were purchased from Cayman (Sapphire Bioscience,
Australia).  Human  Endothelial-SFM  Basal  Growth
Medium  and  fetal  calf  serum  was  obtained  from
GibThai (Thailand). Recombinant human IL-1b , were
purchased from Genzyme (USA). Pure nitrocellulose
membrane  (0.45  micron)  and  filter  paper  were
purchased from BIO-RAD (USA).
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The effect of PGE2 on COX activity as
measured by the production of 6-keto-PGF1a ,
PGE2, PGF2a and TXB2 in HUVEC treated with
IL-1b (1ng/ml)
Untreated HUVEC  in  the presence of arachidonic
acid  (10 m M  for  10min)  release  lower  amounts  of
6-keto-PGF1 a (3.36  ±  0.1 ng/ml),  PGE2 (0.4  ±
0.04 ng/ml),  PGF2 a (0.78  ±  0.01 ng/ml)  and  TXB2
(0.04 ± 0.01 ng/ml). In IL-1b (0.01, 0.1 and 1 ng/ml)
treated  HUVEC;  the  production  of  6-keto-PGF1 a ,
PGE2 and PGF2 a was increased but not TXB2 (Fig. 1).
The  production  of  6-keto-PGF1 a in  HUVEC  treated
with  IL-1b (0.01,  0.1  and  1ng/ml)  was  increased
significantly  in  a  dose-dependent  manner  (Fig.  1A).
This increase was significantly at 0.01 ng/ml of IL-1b .
The others, PGE2 but not PGF2 a , was only increased
significantly  in  HUVEC  treated  with  IL-1b 1 ng/ml
(Fig. 1B). In HUVEC treated with PGE2 (3 m M) alone,
COX metabolites did not change significantly when
compared to untreated HUVEC (Fig. 2). Interestingly,
the increased 6-keto-PGF1 a and PGE2 in IL-1b (1ng/
ml)  treated  HUVEC  was  significantly  inhibited  by
PGE2 (0.03,  0.3  or  3 m M)  in  a  dose-dependent
manner  (Fig.  2).  This  inhibition  was  significant  at
0.03 m M of PGE2.
IL-1b alone, PGE2 alone and IL-1b plus PGE2 did not
affect on cells viability (97 ± 2, 98 ± 1 and 98 ± 1%,
respectively) when compare to the control untreated
cells over a 24-h incubation period.
The stability  of PGE2 (3 m M) in  cultured medium
upto  24 h  was  also  tested  and  has  not  changed
significantly between 3 (2.97 ± 0.2), 6 ( 2.98 ± 0.1),
12 (2.95 ± 0.2) and 24 (2.97 ± 0.2) hours incubation
of PGE2.
The effect of PGE2 on COX isoform expressed
in HUVEC treated with IL-1b
Untreated HUVEC contained no COX-2 protein (Fig.
3). COX-2 protein was expressed in HUVEC  treated
with IL-1b (1ng/ml; Fig. 3) for 24 h. Interestingly, this
induction of COX-2 in HUVEC treated by IL-1b (1ng/
ml) was inhibited by PGE2 (0.03, 0.3 or 3 m M) in  a
dose-dependent manner (Fig. 3). The amount of COX-
1  protein  expressed  in  HUVEC  treated  with  IL-1b
(1ng/ml), IL-1b (1ng/ml) plus PGE2 (3 m M) or PGE2
(3 m M)  alone  was  not  changed  when  compared  to
untreated HUVEC (Fig. 4).
The effect of forskolin on 6-keto-PGF1 a
production in HUVEC treated with IL-1b plus
PGE2
The  COX  activity  (as  measured  by  6-keto-PGF1 a
production)  in  HUVEC  treated  with  forskolin
(100 m M)  plus  PGE2 (3 m M)  or  forskolin  (100 m M)
alone was not  changed in  comparison  with untrea-
ted  HUVEC  (Fig.  5;  white  bar).  Interestingly,  the
inhibition  of increased  COX  activity  in  IL-1b (1ng/
ml) treated HUVEC by PGE2 was reversed in a dose-
dependent  manner  when  cells  were  coincubated
with forskolin (10, 50 or 100 m M; Fig. 5; black and
hatch bar). Moreover, the increased COX activity in
IL-1b (1 ng/ml) treated HUVEC was synergised when
cells were coincubated with forskolin (100 m M; Fig.
5; black bar).
PGE2 inhibit COX-2 induction through cAMP
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FIG. 1. Dose-dependent effects of  IL-1b (1 ng/ml) on COX
activity  in  HUVEC.  COX  activity  was  measured  by  the
formation of 6-keto-PGF1a (panel A), PGE2 (panel B), PGF2a
(panel B) and TXB2 (panel B) in the presence of exogenous
arachidonic  acid  (10 m M;  10min).  Data  are  expressed  as
mean±SEM of 12 determinations from at least four separate
experimental days.  *P<0.05  when  compared  to  untreated
HUVEC at 24h (C).P. Akarasereenont et al.
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FIG. 2. The effects of PGE2 (0.003, 0.03, 0.3 or 3 m M) on COX activity in IL-1b (1ng/ml) treated HUVEC. COX activity was
measured by the formation of 6-keto-PGF1a (panel A), PGE2 (panel B), PGF2a (panel B) and TXB2 (panel B) in the presence of
exogenous arachidonic acid  (10 m M; 10min). Data are expressed as  mean±SEM  of  12 determinations from  at least four
separate experimental days. *P<0.05 when compared to IL-1b treated HUVEC at 24h.Forskolin alone, forskolin plus IL-1b , forskolin plus
PGE2 and forskolin plus IL-1b with PGE2 did not affect
on cells viability (98 ± 2, 95 ± 1, 96 ± 3 and 94 ± 3%,
respectively) when compared to the control untrea-
ted cells over a 24-h incubation period.
The effect of forskolin on COX isoform expressed
in HUVEC treated with IL-1b plus PGE2
HUVEC  treated  with  forskolin  (100 m M)  alone  or
forskolin (100 m M) plus PGE2 (3 m M) contain no COX-2
PGE2 inhibit COX-2 induction through cAMP
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FIG. 3. The effects of PGE2 on COX-2 protein expressed in IL-
1b (1ng/ml) treated HUVEC. COX-2 protein was detected by
Western blots using polyclonal antibodies to COX-2 in cell
extracts of HUVEC treated with no addition (lane 1), PGE2
(3 m M) alone (lane 2), IL-1b (1ng/ml) alone (lane 3) or IL-1b
(1ng/ml) plus PGE2 (0.03, 0.3 or 3 m M; lane 4 to 6) for 24h.
Equal amounts of protein (20 m g/lane) were loaded in each
lane. Similar results were obtained with cell extracts from
three separate batches of cells. The significant differences
between  each  band  were  compared  by  scanner  densito-
metry using image 1D program (densitometry unit).
FIG. 4. The effects of PGE2 on COX-1 protein expressed in IL-
1b (1ng/ml) treated HUVEC. COX-1 protein was detected by
Western blots using polyclonal antibodies to COX-2 in cell
extracts of HUVEC treated with no addition (lane 1), PGE2
(3 m M) alone (lane 2), IL-1b (1ng/ml) alone (lane 3) or IL-1b
(1ng/ml) plus PGE2 (0.03, 0.3 or 3 m M; lanes 4–6) for 24h.
Equal amounts of protein (20 m g/lane) were loaded in each
lane. Similar results were obtained with cell extracts from
three separate batches of cells. The significant differences
between  each  band  were  compared  by  scanner  densito-
metry using image 1D program (densitometry unit).
FIG. 5. The effects of forskolin (10, 50 or 100 m M) on COX activity in IL-1b (1ng/ml) plus PGE2 (3 m M) treated HUVEC. COX
activity was measured by the formation of 6-keto-PGF1a in the presence of exogenous arachidonic acid (10 m M; 10min). Data
are expressed as mean±SEM of 12 determinations from at least four separate experimental days. *P<0.05 when compared to
IL-1b plus PGE2 treated HUVEC at 24h. **P<0.05 when compared to IL-1b treated HUVEC at 24h.P. Akarasereenont et al.
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FIG. 6. The effects of forskolin on COX-2 protein expressed in IL-1b (1ng/ml) plus PGE2 (3 m M) treated HUVEC. COX-2 protein
was detected by Western blots using polyclonal antibodies to COX-2 in cell extracts of HUVEC treated with no addition (lane
1), PGE2 (3 m M; lane 2) alone, forskolin (100 m M; lane 3) alone, IL-1b (1ng/ml; lane 4) alone, IL-1b (1ng/ml) plus PGE2 (3 m M; lane
5), IL-1b (1ng/ml) plus PGE2 (3 m M) with forskolin (100 m M; lane 6), IL-1b (1ng/ml) plus forskolin (100 m M; lane 7) or PGE2 (3 m M)
plus forskolin (100 m M; lane 8) for 24h. Equal amounts of protein (20 m g/lane) were loaded in each lane. Similar results were
obtained with cell extracts from three separate batches of cells. The significant differences between each band were compared
by scanner densitometry using image 1D program (densitometry unit).
protein (Fig. 6; lanes 3 and 8, respectively). Similarly in
COX activity, the inhibition of COX-2 induced in IL-1b
(1ng/ml) treated HUVEC by PGE2 was also reversed
when cells were coincubated with forskolin (100 m M;
Fig. 6; lanes 4 to 6). However, unlike COX activity, the
amounts of COX-2 protein induced in IL-1b (1ng/ml)
treated HUVEC was slightly increased when cells were
coincubated with forskolin (100 m M; Fig. 6; lane 7).
The amount of COX-1 protein expressed in HUVEC
treated with foskolin (100 m M) alone, IL-1b (1ng/ml)
plus PGE2 (3 m M), IL-1b (1 ng/ml) plus PGE2 (3 m M)
with forskolin (100 m M), IL-1b (1ng/ml) plus forskolin
(100 m M) or PGE2 (3 m M) plus forskolin (100 m M) was
not  changed  when  compared  to  untreated  HUVEC
(Fig. 7).
Discussion
Here, we showed that the induction of COX-2 elicited
by IL-1b in HUVEC can be inhibited by PGE2 in a dose-
dependent manner. Moreover, PGE2 had no affect on
either  COX-1  protein  or  activity.  Interestingly,  for-
skolin (cAMP activator) can reverse this inhibition of
PGE2 on COX-2 protein and activity in IL-1b treated
HUVEC.  The  results  suggested  that  (i)  PGE2 is  a
negative  feedback  regulator  through  cAMP  in  the
induction  of  COX-2  elicited  by  IL-1b in  endothelial
cells  and  (ii)  the  uses  of  PGE2 in  the  condition  in
which  COX-2  has  been  involved  may  be
therapeutic.
PGs induce a wide range of biological actions that
are mediated by specific membrane-bound receptors.
Among the PGs, PGE2 is considered to exert a variety
of  biological  activities  such  as  the  maintenance  of
local  homeostasis  in  the  body,12 it  is  a  major
contributor  to  the  production  and  maintenance  of
immunosuppression after overwhelming injury10 and
an important factor for implantation and decidualiza-
tion.17 Therefore,  PGE2 is  a  lipid  molecule  with
complex  inflammatory  modulation  and  immunor-
egulatory  properties.  Our  results  have  been  sup-
ported  that  PGE2 can  act  as  anti-inflammation  and
immunosuppression  in  the  induction  of  COX-2  in
endothelial cells by IL-1b .
The  exact  mechanisms  by  which  PGE2 inhibited
COX-2 induction in endothelial cells activated with IL-
1b are  not  known. These  may  involve  binding  to
specific cell surface receptors and influencing second
messenger systems through G-proteins. Indeed, these
should be complex because the effects of PGE2 are
exerted  by  a  variety  of  PGE  receptors  which  aredifferent  in  their  signal  transduction  properties.18
There are at least four subtypes of PGE receptors. The
EP1 and EP3 receptors are coupled to Ca2+ mobiliza-
tion and the inhibition of adenylate cyclase, respec-
tively, and the EP2 and EP4 receptors are coupled to
the same signal transduction pathway, stimulation of
adenylate  cyclase.19 However,  our  studies  showed
that  forskolin  (cAMP  activator)  can  reverse  the
inhibiton of PGE2 on COX-2 induced in IL-1b treated
HUVEC suggesting PGE2 may inhibit COX-2 expressed
in IL-1b treated HUVEC through cAMP inhibition via
EP3 receptors.
PGE2 is one of the PGs or COX metabolites, such
as PGI2, PGE2, PGD2, PGF2 a and TXA2, synthesized
by COX-1 and COX-2 which are involved in physiol-
ogy  and  pathology,4–8 respectively.  Each  COX  iso-
form  can  produce  different  COX  metabolites  in
different  cell  types  such  as  PGI2 is  a  major  COX-1
and  COX-2  metabolite  in  endothelial  cells  while
PGE2 is a major COX-2 metabolite in macrophages.20
These differences in  COX metabolite production in
different  cell  types  may  be  resulted  from the  feed-
back  regulation  of  each  COX  metabolite  produced.
Our  results  showed  that  PGE2 (0.03 m M)  inhibited
PGE2 production (30% inhibition; Fig. 2A) more than
PGI2 production  (20%  inhibition;  Fig.  2B)  in  IL-1b
treated endothelial cells. These may explain the COX
metabolites  produced  in  IL-1b treated  endothelial
cells that  PGI2 released in highest amounts and the
lesser extent of PGE2, PGF2 a and TXA2, respectively.
Thus, elucidation of the feedback regulation of each
COX  metabolite  will  help  us  to  understand  the
variety  of  COX  metabolites  produced  in  different
cells  and  may  lead  to  potential  therapeutic  inter-
ventions. In our studies here, we showed that PGE2
is a negative feedback regulator of the induction of
COX-2, but not COX-1, in endothelial cells activated
with IL-1b . These suggested that PGE series may have
negative feedback regulation of COX-2 induction in
endothelial  cells,  since  our  previous  study  showed
that  PGE1 and  PGE0 can  inhibit  the  induction  of
COX-2 in endothelial cells activated with LPS.13 PGE
series  have  been  used  in  clinical  disorders  such  as
peripheral  vascular  occlusive  diseases,21 NSAIDs-
induced gastric ulcer,22 abortion23 and impotence.24
Thus, we proposed that  uses of PGE2 in  the condi-
tion  in  which  COX-2  has  been  involved  may  be
therapeutic and the effects of other COX metabolites
such  as  PGI2 or  PGF2 a on  COX-2  expressed  in
different cells should be elucidated.
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FIG. 7. The effects of forskolin on COX-1 protein expressed in IL-1b (1ng/ml) plus PGE2 (3 m M) treated HUVEC. COX-1 protein
was detected by Western blots using polyclonal antibodies to COX-1 in cell extracts of HUVEC treated with no addition (lane
1), PGE2 (3 m M; lane 2) alone, forskolin (100 m M; lane 3) alone, IL-1b (1ng/ml; lane 4) alone, IL-1b (1ng/ml) plus PGE2 (3 m M; lane
5), IL-1b (1ng/ml) plus PGE2 (3 m M) with forskolin (100 m M; lane 6), IL-1b (1ng/ml) plus forskolin (100 m M; lane 7) or PGE2 (3 m M)
plus forskolin (100 m M; lane 8) for 24h. Equal amounts of protein (20 m g/lane) were loaded in each lanes. Similar results were
obtained with cell extracts from three separate batches of cells. The significant differences between each band were compared
by scanner densitometry using image 1D program (densitometry unit).References
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